Adelaide Research & Scholarship: Search

Search

Results 21-30 of 70 (Search time: 0.002 seconds).

previous
1
2
3
4
5
6
...
7
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2016	Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance	Walia, M.; Ho, P.; Taylor, S.; Ng, A.; Gupte, A.; Chalk, A.; Zannettino, A.; Martin, T.; Walkley, C.
	2015	Bone marrow recovery by morphometry during induction chemotherapy for acute lymphoblastic leukemia in children	Nguyen, T.; Melville, A.; Nath, S.; Story, C.; Howell, S.; Sutton, R.; Zannettino, A.; Revesz, T.; Bandapalli, O.
	2015	Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo	Cheong, C.; Chow, A.; Fitter, S.; Hewett, D.; Martin, S.; Williams, S.; To, L.; Zannettino, A.; Vandyke, K.
	2013	Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step	Richardson, J.; Nelson, A.; Zannettino, A.; Gronthos, S.; Worthley, S.; Psaltis, P.
	2013	Impact of timing and dose of mesenchymal stromal cell therapy in a preclinical model of acute myocardial infarction	Richardson, J.; Bertaso, A.; Psaltis, P.; Frost, L.; Carbone, A.; Paton, S.; Nelson, A.; Wong, T.; Worthley, M.; Gronthos, S.; Zannettino, A.; Worthley, S.
	2010	The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo	Vandyke, K.; Dewar, A.; Diamond, P.; Fitter, S.; Schultz, C.; Sims, N.; Zannettino, A.
	2010	Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations	Psaltis, P.; Paton, S.; See, F.; Arthur, A.; Martin, S.; Itescu, S.; Worthley, S.; Gronthos, S.; Zannettino, A.
	2010	NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells	Martin, S.; Fitter, S.; Bong, L.; Drew, J.; Gronthos, S.; Shepherd, P.; Zannettino, A.
	2016	Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models	Liapis, V.; Zinonos, I.; Labrinidis, A.; Hay, S.; Ponomarev, V.; Panagopoulos, V.; Zysk, A.; DeNichilo, M.; Ingman, W.; Atkins, G.; Findlay, D.; Zannettino, A.; Evdokiou, A.
	2013	An injectable hydrogel incorporating mesenchymal precursor cells and pentosan polysulphate for intervertebral disc regeneration	Frith, J.; Cameron, A.; Menzies, D.; Ghosh, P.; Whitehead, D.; Gronthos, S.; Zannettino, A.; Cooper-White, J.